Please assess the completion status of the following clinical trial:

Trial Title: Ocrelizumab or Alemtuzumab Compared With Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis - a Phase-2 Randomised Controlled Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria (Based on CARE-MS-II3, guidelines and Rio-criteria for treatment failure):~* Written informed consent and agreement to comply to study protocol~* Age: 18-55 years~* EDSS: 0.0 - 6.0~* RRMS according to McDonald 2010~* \< 10 years of disease course after symptom onset~* Active disease with one of the following treatment failures occur-ring not earlier than 6 months after initiation of an approved DMT~* 2 or more relapses within the last 12 months~or~* 1 relapse within the last 12 months and a Gd-enhancing lesion on MRI \> 3 mm \> 3 months before or after relapse onset or 2 new T2-lesions~or~* On-going signs of MRI activity in the last 6 months (either Gd-en-hancing of ≥ 3 mm lesion at any exam in the last year; or more than 5 new T2 lesions (≥ 3 mm)~or~* Patients stable under natalizumab but who have to stop treatment due to an increasing PML risk are defined as active, if a MRI within 6 months after termination of natalizumab shows new T2 or Gd-enhancing lesions and at least one other treatment fail-ure prior to natalizumab is documented.~Exclusion Criteria:~* Secondary or primary progressive MS~* Pregnancy, or other medical condition incompatible with aHSCT~* Any treatment or medical condition that, according to the haematologist / transplant specialist precludes the use of aHSCT~* John Cunningham virus (JCV) antibody index of \> 1.5 in previ-ously natalizumab-treated patients, if a negative CSF JCV-PCR prior to screening is not available~* Relapse during 30 days before initiation of treatment. If a relapse occurs during this period and eligibility criteria are otherwise ful-filled, start of treatment will be delayed until at least 30 days after receiving steroids.~* Concurrent clinically significant (as determined by the investiga-tors and haematologist / transplant specialist) cardiac, immuno-logical, pulmonary, neurological, renal or other major disease such as:~  * Prominent cardial disease (Left ventricular ejection frac-tion (LVEF) \< 40%, myocardial infarction or ischemia, un-controlled arrhythmias, pericardial effusion \> 1 cm)~ * Cerebrovascular disease~ * Renal disease (creatinine clearance \< 30 ml/min/m2)~ * Respiratory disease (DLCO \< 40% predicted)~ * Active bleeding or clotting disease~ * History of human immunodeficiency virus (HIV) or posi-tive HIV antibody testing~ * Any uncontrolled acute or chronic infection, including HIV, hepatitis B surface antigen positivity and hepatitis C PCR positivity~ * Cancer except in situ cervix or cutaneous~* Unwillingness or inability to comply with the requirements of this protocol including the presence of any condition (physical, men-tal, or social) that is likely to affect the patient returning for follow-up visits on schedule. Unwillingness to use contraception.~* Previous participation in this study, previous treatment with aHSCT or already both comparators~* Ongoing immunotherapy. Treatment with interferon or glati-rameracetate will need no wash-out. Treatment pause before oc-relizumab/alemtuzumab or aHSCT will be:~  * for dimethylfumarate and fingolimod: 8 weeks~ * for natalizumab: 8 weeks~ * for ocrelizumab: 12 weeks~ * for alemtuzumab: 12 months~ * for teriflunomide: 4 weeks after elimination with cholesty-ramine~ * for cladribine: 24 weeks~* Patients with cognitive impairments who are unable to provide written, informed consent prior to any testing under this protocol, including screening and baseline investigations that are not con-sidered part of routine patient care.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Intervention (aHSCT) (Type: EXPERIMENTAL): Autologous Hematopoietic Stem Cell Transplantation. Mobilisation will be performed with 2 g/m2 cyclophosphamide and 10 μg/kg G-CSF from day 5 until apheresis is completed. Conditioning will be 200 mg/kg cyclo-phosphamide and Anti-T-lymphocyteglobuline (Grafalon®, Neovii) with cu-mulative doses of 20 mg/kg given on day +1 (10 mg/kg) and day +2 (10 mg/kg).
- Control (Type: ACTIVE_COMPARATOR): In the control arm patient and physician will decide which treatment to choose. Patients will be either treated with ocrelizumab according to the SmPC (600 mg every 6 months continuously) or with alemtuzumab according to the SmPC (12 mg/day for 5 consecutive days and again after 365 days for 3 days).

Based on this trial design, predict the completion outcome and termination type (if applicable).